AR125338A1 - Conjugados de pirrolobenzodiazepina - Google Patents
Conjugados de pirrolobenzodiazepinaInfo
- Publication number
- AR125338A1 AR125338A1 ARP220100927A ARP220100927A AR125338A1 AR 125338 A1 AR125338 A1 AR 125338A1 AR P220100927 A ARP220100927 A AR P220100927A AR P220100927 A ARP220100927 A AR P220100927A AR 125338 A1 AR125338 A1 AR 125338A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- alkyl
- group
- compound
- optionally substituted
- Prior art date
Links
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 17
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 abstract 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 5
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 abstract 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 4
- 125000005647 linker group Chemical group 0.000 abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 4
- 125000004076 pyridyl group Chemical group 0.000 abstract 4
- 125000001544 thienyl group Chemical group 0.000 abstract 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000000172 C5-C10 aryl group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- IBAHLNWTOIHLKE-UHFFFAOYSA-N cyano cyanate Chemical compound N#COC#N IBAHLNWTOIHLKE-UHFFFAOYSA-N 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 150000002825 nitriles Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 108010016626 Dipeptides Proteins 0.000 abstract 1
- 238000006751 Mitsunobu reaction Methods 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2105186.7A GB202105186D0 (en) | 2021-04-12 | 2021-04-12 | Pyrrolobenzodiazepine conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125338A1 true AR125338A1 (es) | 2023-07-05 |
Family
ID=75949544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100927A AR125338A1 (es) | 2021-04-12 | 2022-04-12 | Conjugados de pirrolobenzodiazepina |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR125338A1 (fr) |
| GB (1) | GB202105186D0 (fr) |
| TW (1) | TW202308697A (fr) |
| WO (1) | WO2022218973A2 (fr) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58180487A (ja) | 1982-04-16 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | 抗生物質ｄｃ−８１およびその製造法 |
| CA2558195C (fr) | 2004-03-01 | 2012-11-06 | Spirogen Limited | Derives de 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepine-5-one en tant qu'intermediaires cles pour la preparation de pyrrolobenzodiazepines substituees c2 |
| DE602006011300D1 (de) | 2005-04-21 | 2010-02-04 | Spirogen Ltd | Pyrrolobenzodiazepine |
| EP1813614B1 (fr) | 2006-01-25 | 2011-10-05 | Sanofi | Agents cytotoxiques comprenant de nouveaux dérivés de Tomaymycine |
| ES2523915T5 (es) | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
| US20110256157A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2012064733A2 (fr) | 2010-11-09 | 2012-05-18 | Medimmune, Llc | Échafaudage d'anticorps pour conjugaison homogène |
| KR101412875B1 (ko) | 2012-10-04 | 2014-07-02 | 삼성전기주식회사 | 게이트 구동 회로 및 이를 갖는 인버터 |
| CN104837502B (zh) | 2012-10-12 | 2018-08-10 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
| ES2658888T5 (es) | 2012-12-21 | 2021-10-19 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| JP6685924B2 (ja) | 2014-04-11 | 2020-04-22 | メディミューン，エルエルシー | システイン操作抗体を含むコンジュゲート化合物 |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201617466D0 (en) * | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| MA46789A (fr) | 2016-11-10 | 2019-09-18 | Medimmune Llc | Molécules de liaison spécifiques d'asct2 et leurs utilisations |
| WO2019034764A1 (fr) | 2017-08-18 | 2019-02-21 | Medimmune Limited | Conjugués de pyrrolobenzodiazépine |
| WO2019224340A1 (fr) | 2018-05-25 | 2019-11-28 | Medimmune Limited | Conjugués de pyrrolobenzodiazépine |
| BR112020025212A2 (pt) * | 2018-07-05 | 2021-03-09 | Hangzhou Dac Biotech Co., Ltd | Derivado de dímero de pirrolobenzodiazepina cruzadamente ligado, conjugado de um derivado de dímero de pirrolobenzodiazepina cruzadamente ligado a uma molécula de ligação à célula, l1 e l2, agente de ligação à célula/molécula de ligação à célula, célula tumoral, composição farmacêutica, e, agentes quimioterapêutico e sinérgicos |
| KR20210076056A (ko) * | 2018-10-12 | 2021-06-23 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 2,3-다이아미노석신일기를 함유하는 접합 링커 |
| GB2581394A (en) * | 2019-02-18 | 2020-08-19 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
-
2021
- 2021-04-12 GB GBGB2105186.7A patent/GB202105186D0/en not_active Ceased
-
2022
- 2022-04-12 AR ARP220100927A patent/AR125338A1/es unknown
- 2022-04-12 WO PCT/EP2022/059733 patent/WO2022218973A2/fr active Application Filing
- 2022-04-12 TW TW111113931A patent/TW202308697A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022218973A3 (fr) | 2022-12-22 |
| WO2022218973A2 (fr) | 2022-10-20 |
| TW202308697A (zh) | 2023-03-01 |
| GB202105186D0 (en) | 2021-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080688A1 (es) | Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas como antagonistas de trpv1 y su preparacion | |
| AR112689A1 (es) | Agonistas del receptor tipo toll 7 (tlr7) que tienen porciones aromáticas ligadas al heteroátomo, conjugados de estos y métodos y usos de estos | |
| BR112019006816A2 (pt) | compostos de benzo[b]tiofeno como agonistas de sting, composição farmacêutica e uso dos mesmos | |
| EA202091479A1 (ru) | Арил- и гетероарилзамещенные индольные соединения | |
| PE20170775A1 (es) | Derivados de benzodiazepina citotoxicos | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| EA202091508A1 (ru) | 6-азаиндольные соединения | |
| CY1117157T1 (el) | Υποκατεστημενο παραγωγο ισοκινολινης | |
| BRPI0606319A2 (pt) | compostos farmacêuticos | |
| AR095192A1 (es) | Quinolina y quinazolinamidas como modulares de canales de sodio | |
| EA202091530A1 (ru) | Диазаиндольные соединения | |
| AR049333A1 (es) | Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas. | |
| AR092538A1 (es) | Inhibidores de girasa triciclica | |
| AR067779A1 (es) | Profarmacos dipeptoides y su uso | |
| MD3820873T2 (ro) | Degradanți selectivi ai receptorului estrogen | |
| CL2019002919A1 (es) | Compuestos inhibidores vmat2 y composiciones relacionadas. | |
| CO6020016A1 (es) | Derivados de 1,2,4,5 tetrahidro-3h-benzapezinas su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
| AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
| ECSP066349A (es) | Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales | |
| AR053340A1 (es) | Derivados de trifluormetilbenzamida y sus usos terapeuticos | |
| AR061973A1 (es) | Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos | |
| NI201000134A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| AR040398A1 (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, composiciones farmaceuticas que los contienen y su uso para preparar un medicamento | |
| AR102258A1 (es) | Compuestos de quinolina y quinazolina | |
| AR045156A1 (es) | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |